You just read:

AbbVie Receives Health Canada Approval for the Combination of VENCLEXTA® (venetoclax) with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia

News provided by

AbbVie Canada

May 05, 2020, 07:01 ET